Literature DB >> 33659542

Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes.

Laura P Hughes1, Glenda M Halliday1, Nicolas Dzamko1.   

Abstract

Glucocerebrosidase (GCase) is an important enzyme for the metabolism of glycolipids. GCase enzyme deficiency is implicated in human disease and the efficient measurement of GCase activity is important for evaluating the efficacy of therapeutics targeting this enzyme. Existing approaches to measure GCase activity include whole blood mass spectrometry-based assays, where an internal standard is used to measure the accumulation of ceramide following metabolism of the synthetic substrate C12-glucocerebroside, and the utilisation of fluorescent probes that bind active GCase and/or release fluorescent metabolites upon cleavage by GCase. Here, we describe the application of a fluorescence-activated cell sorter-based assay to efficiently quantitate GCase enzyme activity in the monocyte population of human peripheral blood mononuclear cells. The cell-permeable GCase substrate 5-(Pentafluorobenzoylamino) Fluorescein Di-beta-D-Glucopyranoside (PFB-FDGlu) provides a means to measure GCase activity, whereby enzymatic cleavage yields the green-fluorescent PFB-F dye, detectable in the FL-1 channel of a flow cytometer. An inhibitor of lysosomal GCase activity, conduritol B-epoxide, is employed to ensure specificity. This protocol provides an advantageous approach for measuring GCase activity in living individual cells.
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Enzyme; Flow cytometry; GBA; Glucocerebrosidase; Lipid; Monocyte

Year:  2020        PMID: 33659542      PMCID: PMC7842359          DOI: 10.21769/BioProtoc.3572

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  18 in total

1.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

2.  The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.

Authors:  Richie Khanna; Elfrida R Benjamin; Lee Pellegrino; Adriane Schilling; Brigitte A Rigat; Rebecca Soska; Hadis Nafar; Brian E Ranes; Jessie Feng; Yi Lun; Allan C Powe; David J Palling; Brandon A Wustman; Raphael Schiffmann; Don J Mahuran; David J Lockhart; Kenneth J Valenzano
Journal:  FEBS J       Date:  2010-02-10       Impact factor: 5.542

3.  Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease.

Authors:  Bernard Rudensky; Esther Paz; Gheona Altarescu; David Raveh; Deborah Elstein; Ari Zimran
Journal:  Blood Cells Mol Dis       Date:  2003 Jan-Feb       Impact factor: 3.039

4.  Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

Authors:  Roy N Alcalay; Oren A Levy; Cheryl C Waters; Stanley Fahn; Blair Ford; Sheng-Han Kuo; Pietro Mazzoni; Michael W Pauciulo; William C Nichols; Ziv Gan-Or; Guy A Rouleau; Wendy K Chung; Pavlina Wolf; Petra Oliva; Joan Keutzer; Karen Marder; Xiaokui Zhang
Journal:  Brain       Date:  2015-06-27       Impact factor: 13.501

5.  Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2.

Authors:  Rolf G Boot; Marri Verhoek; Wilma Donker-Koopman; Anneke Strijland; Jan van Marle; Hermen S Overkleeft; Tom Wennekes; Johannes M F G Aerts
Journal:  J Biol Chem       Date:  2006-11-14       Impact factor: 5.157

6.  Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity.

Authors:  M Lorincz; L A Herzenberg; Z Diwu; J A Barranger; W G Kerr
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

7.  Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.

Authors:  Suzanne Lesage; Mathieu Anheim; Christel Condroyer; Pierre Pollak; Franck Durif; Céline Dupuits; François Viallet; Ebba Lohmann; Jean-Christophe Corvol; Aurélie Honoré; Sophie Rivaud; Marie Vidailhet; Alexandra Dürr; Alexis Brice
Journal:  Hum Mol Genet       Date:  2010-10-14       Impact factor: 6.150

8.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

Review 9.  Gaucher disease: insights from a rare Mendelian disorder.

Authors:  Ellen Sidransky
Journal:  Discov Med       Date:  2012-10       Impact factor: 2.970

10.  Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.

Authors:  Alisdair McNeill; Joana Magalhaes; Chengguo Shen; Kai-Yin Chau; Derralyn Hughes; Atul Mehta; Tom Foltynie; J Mark Cooper; Andrey Y Abramov; Matthew Gegg; Anthony H V Schapira
Journal:  Brain       Date:  2014-02-25       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.